DURHAM, N.C. and BEIJING, May 8, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon ...
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage ...
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 ...
[Audio Gap] Please be advised that today's call is being recorded. This call will be conducted in English. This is Kathy Yu, Associate Director of Investor Relations. Welcome to Brii Bio's 2025 Full ...
End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative ...
English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at 8:30 a.m. HKT / March 19 at 8:30 p.m. ET Alongside its HBV cure programs, Brii Bio has expanded its discovery ...
Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy With effective cost control measures in place, Brii Bio remains well-capitalized, maintaining a cash position of ...
DURHAM, N.C. and BEIJING, China, March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited (" Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results